Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Factors associated with the risk of intestinal ulcers flare-ups

From: Poor prognostic factors in patients with newly diagnosed intestinal Adamantiades-Behçet’s disease in the Shanghai Adamantiades-Behçet’s disease database: a prospective cohort study

 Univariate analysisMultivariate analysis
OR (95% CI)POR (95% CI)P
Male sex2.28 (0.46–11.25)0.441
Age at the diagnosis of BS > 35 years2.64 (0.54–13.03)0.262
Onset of BS (< 7 years)1.31 (0.31–5.58)1.000
Intestinal symptoms4.72 (0.59–37.90)0.1325.14 (0.58–45.12)0.140
Endoscopic characteristics
Location (ileocecal and colorectum)0.59 (0.08–4.67)1.000
Number, ≥ 30.16 (0.02–1.31)0.0600.15 (0.02–1.29)0.084
Size, > 1 cm3.07 (0.73–12.96)0.196
Lab parameters
WBC > 6.4, × 109/L0.76 (0.18–3.25)1.000
Hb < 123, g/L0.79 (0.19–3.38)1.000
ESR > 24, mm/h1.36 (0.32–5.78)0.716
CRP > 10, mg/L2.55 (0.52–12.57)0.271
Positive FOBT+1.50 (0.31–7.22)0.617
Positive T-SPOT0.79 (0.10–6.18)1.000
HBV-DNA6.87 (1.66–28.36)0.287
Treatment    
Biologics1.83 (0.37–9.00)0.697
IFX therapy#1.41 (0.33–6.00)0.711
Poor compliance0.38 (0.05–3.06)0.673
  1. +FOBT: fecal occult blood test
  2. #IFX therapy was administrated at 0,2, and 6 weeks (intravenous), and then maintained with the same dosage of IFX every 8 weeks